{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-063967","form_type":"8-K","ticker":"HRTX","cik":"0000818033","company_name":"HERON THERAPEUTICS, INC. /DE/","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.386601+00:00","generated_at":"2026-05-22T15:39:39.104532+00:00","sec_items":["8.01","9.01"],"event_type":"litigation","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Heron settles patent litigation with Mylan, grants generic license for CINVANTI/APONVIE starting June 2032","bullets":["Settlement resolves patent litigations in U.S. District Court for Delaware initiated in Sep 2023 and Jan 2024.","Heron grants Mylan a license to market generic CINVANTI and APONVIE beginning June 1, 2032 (or earlier under certain circumstances).","Patent protection for CINVANTI and APONVIE extends to 2035; license starts ~3 years before expiration.","Parties will file stipulation to dismiss pending litigations."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-063967","json":"https://secwatch.observer/filing/0000950170-25-063967.json","markdown":"https://secwatch.observer/filing/0000950170-25-063967.md","text":"https://secwatch.observer/filing/0000950170-25-063967.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818033/000095017025063967/0000950170-25-063967-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818033/000095017025063967/hrtx-20250506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T15:39:39.104532+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}